These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1730 related articles for article (PubMed ID: 28176481)

  • 41. Multidrug-Resistant Gram-Negative Bacterial Infections in the Hospital Setting: Overview, Implications for Clinical Practice, and Emerging Treatment Options.
    Cerceo E; Deitelzweig SB; Sherman BM; Amin AN
    Microb Drug Resist; 2016 Jul; 22(5):412-31. PubMed ID: 26866778
    [TBL] [Abstract][Full Text] [Related]  

  • 42. In vitro activity of doripenem alone and in multi-agent combinations against extensively drug-resistant Acinetobacter baumannii and Klebsiella pneumoniae.
    Clock SA; Tabibi S; Alba L; Kubin CJ; Whittier S; Saiman L
    Diagn Microbiol Infect Dis; 2013 Jul; 76(3):343-6. PubMed ID: 23601454
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Multidrug-resistant and extensively drug-resistant Gram-negative pathogens: current and emerging therapeutic approaches.
    Karaiskos I; Giamarellou H
    Expert Opin Pharmacother; 2014 Jul; 15(10):1351-70. PubMed ID: 24766095
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Search for Shorter Portions of the Proline-Rich Antimicrobial Peptide Fragment Bac5(1-25) That Retain Antimicrobial Activity by Blocking Protein Synthesis.
    Mardirossian M; Sola R; Degasperi M; Scocchi M
    ChemMedChem; 2019 Feb; 14(3):343-348. PubMed ID: 30615305
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Efficacy of ARV-1502, a Proline-Rich Antimicrobial Peptide, in a Murine Model of Bacteremia Caused by Multi-Drug Resistant (MDR)
    Xiong YQ; Li L; Zhou Y; Kraus CN
    Molecules; 2019 Aug; 24(15):. PubMed ID: 31382389
    [No Abstract]   [Full Text] [Related]  

  • 46. Design SMAP29-LysPA26 as a Highly Efficient Artilysin against Pseudomonas aeruginosa with Bactericidal and Antibiofilm Activity.
    Wang T; Zheng Y; Dai J; Zhou J; Yu R; Zhang C
    Microbiol Spectr; 2021 Dec; 9(3):e0054621. PubMed ID: 34878337
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Rapid antimicrobial susceptibility test for identification of new therapeutics and drug combinations against multidrug-resistant bacteria.
    Sun W; Weingarten RA; Xu M; Southall N; Dai S; Shinn P; Sanderson PE; Williamson PR; Frank KM; Zheng W
    Emerg Microbes Infect; 2016 Nov; 5(11):e116. PubMed ID: 27826141
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Efficacy and toxicity of the antimicrobial peptide M33 produced with different counter-ions.
    Pini A; Lozzi L; Bernini A; Brunetti J; Falciani C; Scali S; Bindi S; Di Maggio T; Rossolini GM; Niccolai N; Bracci L
    Amino Acids; 2012 Jul; 43(1):467-73. PubMed ID: 21984381
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Lysine-Based Small Molecule Sensitizes Rifampicin and Tetracycline against Multidrug-Resistant
    Konai MM; Haldar J
    ACS Infect Dis; 2020 Jan; 6(1):91-99. PubMed ID: 31646866
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Evolution of susceptibility to antibiotics of Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa and Acinetobacter baumanii, in a University Hospital Center of Beirut between 2005 and 2009].
    Hamouche E; Sarkis DK
    Pathol Biol (Paris); 2012 Jun; 60(3):e15-20. PubMed ID: 21719212
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Evolution of antimicrobial resistance among Pseudomonas aeruginosa, Acinetobacter baumannii and Klebsiella pneumoniae in Brooklyn, NY.
    Landman D; Bratu S; Kochar S; Panwar M; Trehan M; Doymaz M; Quale J
    J Antimicrob Chemother; 2007 Jul; 60(1):78-82. PubMed ID: 17490999
    [TBL] [Abstract][Full Text] [Related]  

  • 52. In vitro effects of sulbactam combinations with different antibiotic groups against clinical Acinetobacter baumannii isolates.
    Deveci A; Coban AY; Acicbe O; Tanyel E; Yaman G; Durupinar B
    J Chemother; 2012 Oct; 24(5):247-52. PubMed ID: 23182043
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Antimicrobial activities and membrane-active mechanism of CPF-C1 against multidrug-resistant bacteria, a novel antimicrobial peptide derived from skin secretions of the tetraploid frog Xenopus clivii.
    Xie J; Gou Y; Zhao Q; Wang K; Yang X; Yan J; Zhang W; Zhang B; Ma C; Wang R
    J Pept Sci; 2014 Nov; 20(11):876-84. PubMed ID: 25098547
    [TBL] [Abstract][Full Text] [Related]  

  • 54. In vitro synergy studies using aztreonam and fluoroquinolone combinations against six species of Gram-negative bacilli.
    Critchley IA; Sahm DF; Kelly LJ; Karlowsky JA
    Chemotherapy; 2003 May; 49(1-2):44-8. PubMed ID: 12714810
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Antimicrobial activity of novel chalcones and modulation of virulence factors in hospital strains of Acinetobacter baumannii and Pseudomonas aeruginosa.
    Ušjak D; Ivković B; Božić DD; Bošković L; Milenković M
    Microb Pathog; 2019 Jun; 131():186-196. PubMed ID: 30980878
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Development of novel ultrashort antimicrobial peptide nanoparticles with potent antimicrobial and antibiofilm activities against multidrug-resistant bacteria.
    Almaaytah A; Mohammed GK; Abualhaijaa A; Al-Balas Q
    Drug Des Devel Ther; 2017; 11():3159-3170. PubMed ID: 29138537
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Influence of antimicrobial consumption on gram-negative bacteria in inpatients receiving antimicrobial resistance therapy from 2008-2013 at a tertiary hospital in Shanghai, China.
    Guo W; He Q; Wang Z; Wei M; Yang Z; Du Y; Wu C; He J
    Am J Infect Control; 2015 Apr; 43(4):358-64. PubMed ID: 25838134
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Antimicrobial susceptibility pattern of nosocomial gram negative pathogens: results from MYSTIC study in Hacettepe University Adult Hospital (2000-2004)].
    Zarakolu P; Hasçelik G; Unal S
    Mikrobiyol Bul; 2006 Jul; 40(3):147-54. PubMed ID: 17001842
    [TBL] [Abstract][Full Text] [Related]  

  • 59.
    Chen H; Li H; Liu Z; Li J
    Microb Drug Resist; 2020 Sep; 26(9):1108-1119. PubMed ID: 32349617
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Repurposing Azithromycin and Rifampicin Against Gram-Negative Pathogens by Combination With Peptidomimetics.
    Baker KR; Jana B; Hansen AM; Nielsen HM; Franzyk H; Guardabassi L
    Front Cell Infect Microbiol; 2019; 9():236. PubMed ID: 31334131
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 87.